We associated the expression of fusion events involving genes on chromosomes 17, such as UTP6-CRLF3 and CPD-PXT1, to the loss of NF1. The detection of these “hidden” alterations required the integration of different layers of genomic data (mutation analysis and copy number alterations), highlighting the complexity of the genomic alterations in AML and the importance of an accurate characterization of each patient’s alterations to permit a personalized medicine approach. This evidence concerns the gene PXT1 and acute myeloid leukemia.